{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:06:54Z","timestamp":1790723214876,"version":"4.1.0"},"reference-count":141,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ctrv.2026.103096","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T16:52:59Z","timestamp":1769619179000},"page":"103096","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Integrating antibody-drug conjugates into the management of early breast cancer"],"prefix":"10.1016","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0231-019X","authenticated-orcid":false,"given":"Maria Ib\u00e1\u00f1ez","family":"Alda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Grinda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9184-7199","authenticated-orcid":false,"given":"Barbara","family":"Pistilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2026.103096_b0005","unstructured":"Cancer Today [Internet]. [cited 2025 May 11]. Available from: https:\/\/gco.iarc.who.int\/today\/."},{"issue":"12","key":"10.1016\/j.ctrv.2026.103096_b0010","doi-asserted-by":"crossref","first-page":"10211","DOI":"10.3390\/curroncol30120743","article-title":"Sequencing antibody drug conjugates in breast cancer: exploring future roles","volume":"30","author":"Fenton","year":"2023","journal-title":"Curr Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103096_b0015","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1080\/14712598.2021.1936494","article-title":"Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics","volume":"21","author":"Saini","year":"2021","journal-title":"Expert Opin Biol Ther"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103096_b0020","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","article-title":"The journey of antibody\u2013drug conjugates: lessons learned from 40 years of development","volume":"14","author":"Colombo","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2026.103096_b0025","article-title":"Rise of antibody-drug conjugates: the present and future","volume":"43","author":"Shastry","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103096_b0030","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ctrv.2026.103096_b0035","doi-asserted-by":"crossref","unstructured":"Chang HL, Schwettmann B, McArthur HL, Chan IS. Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response. J Clin Invest. 133(18):e172156.","DOI":"10.1172\/JCI172156"},{"issue":"315","key":"10.1016\/j.ctrv.2026.103096_b0040","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac4925","article-title":"Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4\/PD-1 blockade","volume":"7","author":"M\u00fcller","year":"2015","journal-title":"Sci Transl Med"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103096_b0045","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.3390\/pharmaceutics16091146","article-title":"Synergizing immunotherapy and antibody\u2013drug conjugates: new horizons in breast cancer therapy","volume":"16","author":"Pinto","year":"2024","journal-title":"Pharmaceutics"},{"issue":"17_suppl","key":"10.1016\/j.ctrv.2026.103096_b0050","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA109","article-title":"Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1\u2013positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04\/KEYNOTE-D19 study","volume":"43","author":"Tolaney","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103096_b0055","doi-asserted-by":"crossref","unstructured":"Schmid, P. et al. Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment (tx) for unresectable locally advanced\/metastatic triple-negative breast cancer (a\/mTNBC): Final results from the phase Ib\/II BEGONIA study. In Berlin, Germany; 2025.","DOI":"10.1016\/j.annonc.2025.08.978"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103096_b0060","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s11864-023-01072-5","article-title":"Antibody-drug conjugate revolution in breast cancer: the road ahead","volume":"24","author":"Grinda","year":"2023","journal-title":"Curr Treat Options Oncol"},{"issue":"19","key":"10.1016\/j.ctrv.2026.103096_b0065","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103096_b0070","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"issue":"10390","key":"10.1016\/j.ctrv.2026.103096_b0075","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103096_b0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103096_b0085","unstructured":"Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer | New England Journal of Medicine [Internet]. [cited 2025 Oct 30]. Available from: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2508668."},{"issue":"16","key":"10.1016\/j.ctrv.2026.103096_b0090","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"issue":"10411","key":"10.1016\/j.ctrv.2026.103096_b0095","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ctrv.2026.103096_b0100","unstructured":"Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer | New England Journal of Medicine [Internet]. [cited 2025 Oct 24]. Available from: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2511734."},{"issue":"3","key":"10.1016\/j.ctrv.2026.103096_b0105","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor\u2013positive human epidermal growth factor receptor 2\u2013negative breast cancer: primary results from TROPION-breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103096_b0110","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.annonc.2025.01.009","article-title":"VP1-2025: Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+\/HER2\u2013) breast cancer (BC): final overall survival (OS) from the phase III TROPION-Breast01 trial","volume":"36","author":"Pistilli","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103096_b0115","unstructured":"Final analysis reports a lack of overall survival benefit with datopotamab deruxtecan in HR+\/HER2\u2013 breast cancer compared to chemotherapy [Internet]. [cited 2025 Dec 22]. Available from: https:\/\/dailyreporter.esmo.org\/news\/final-analysis-reports-a-lack-of-overall-survival-benefit-with-datopotamab-deruxtecan-in-hr-her2-breast-cancer-compared-to-chemotherapy."},{"key":"10.1016\/j.ctrv.2026.103096_b0120","doi-asserted-by":"crossref","unstructured":"Dent RA; Shao Z; Schmid P; et al. First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase 3 TROPION-Breast02 trial. In Berlin, Germany; 2025.","DOI":"10.1016\/j.annonc.2025.09.031"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2026.103096_b0125","article-title":"Sacituzumab tirumotecan (SKB264\/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): results from the phase III OptiTROP-Breast01 study","volume":"42","author":"Xu","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103096_b0130","doi-asserted-by":"crossref","unstructured":"Fan Y, et al. Sacituzumab tirumotecan (sac-TMT) vs investigator\u2019s choice of chemotherapy (ICC) in previously treated locally advanced or metastatic hormone receptor-positive, HER2-negative (HR+\/HER2-) breast cancer (BC): Results from the randomized, multi-center phase III OptiTROP-Breast02 study. In Berlin, Germany; 2025.","DOI":"10.1016\/j.annonc.2025.09.033"},{"key":"10.1016\/j.ctrv.2026.103096_b0135","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-24-01360","article-title":"Surrogate end points for overall survival in neoadjuvant randomized clinical trials for early breast cancer","author":"Conforti","year":"2025","journal-title":"J Clin Oncol."},{"issue":"24","key":"10.1016\/j.ctrv.2026.103096_b0140","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1200\/JCO.20.03613","article-title":"Updated standardized definitions for efficacy end points (STEEP) in adjuvant breast cancer clinical trials: steep version 2.0","volume":"39","author":"Tolaney","year":"2021","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.ctrv.2026.103096_b0145","article-title":"Research status of systemic adjuvant therapy for early breast cancer","volume":"21","author":"Hu","year":"2023","journal-title":"Cancer Control J Moffitt Cancer Cent"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103096_b0150","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35817","article-title":"Correlation analysis of invasive disease\u2010free survival and overall survival in a real\u2010world population of patients with HR+\/HER2\u2013 early breast cancer","volume":"131","author":"Graff","year":"2025","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103096_b0155","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"Von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ctrv.2026.103096_b0160","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1200\/JCO.20.03398","article-title":"Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial","volume":"39","author":"Tolaney","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103096_b0165","doi-asserted-by":"crossref","unstructured":"Geyer C, et al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2\u2013positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05. In Berlin, Germany; 2025.","DOI":"10.1016\/j.annonc.2025.09.021"},{"key":"10.1016\/j.ctrv.2026.103096_b0170","unstructured":"Loibl S, Park YH, Shao Z, Huang CS, Barrios C, Abraham J, et al. Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer. N Engl J Med [Internet]. [cited 2025 Dec 23];0(0). Available from: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2514661."},{"issue":"9938","key":"10.1016\/j.ctrv.2026.103096_b0175","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"32","key":"10.1016\/j.ctrv.2026.103096_b0180","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.2217\/fon-2022-0485","article-title":"ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer","volume":"18","author":"Hurvitz","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.ctrv.2026.103096_b0185","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241248336","article-title":"TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan \u00b1 durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy","volume":"16","author":"Bardia","year":"2024","journal-title":"Ther Adv Med Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103096_b0190","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103096_b0195","doi-asserted-by":"crossref","unstructured":"O\u2019Sullivan CC, Ballman KV, McCall L, Kommalapati A, Zemla T, Weiss A, et al. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1+ tucatinib\/placebo in patients with residual HER2-positive invasive breast cancer. Future Oncol. 17(34):4665\u201376.","DOI":"10.2217\/fon-2021-0753"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2026.103096_b0200","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS602","article-title":"Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA","volume":"39","author":"Marm\u00e9","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103096_b0205","unstructured":"Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy | New England Journal of Medicine [Internet]. [cited 2025 Aug 17]. Available from: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1612645."},{"key":"10.1016\/j.ctrv.2026.103096_b0210","unstructured":"German Cancer Research Center. Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer - a Multicenter, Open-label, Umbrella Phase-II Study - COGNITION-GUIDE [Internet]. clinicaltrials.gov; 2023 July [cited 2025 Mar 6]. Report No.: NCT05332561. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05332561."},{"key":"10.1016\/j.ctrv.2026.103096_b0215","doi-asserted-by":"crossref","unstructured":"HER2-Overexpressing\/Amplified Breast Cancer as a Testing Ground for Antibody\u2013Drug Conjugate Drug Development in Solid Tumors | Clinical Cancer Research | American Association for Cancer Research [Internet]. [cited 2025 Dec 30]. Available from: https:\/\/aacrjournals.org\/clincancerres\/article-abstract\/26\/4\/775\/83104\/HER2-Overexpressing-Amplified-Breast-Cancer-as-a?redirectedFrom=fulltext.","DOI":"10.1158\/1078-0432.CCR-18-1976"},{"key":"10.1016\/j.ctrv.2026.103096_b0220","unstructured":"Almeida LFC de, Leite LF, Cappellaro AP, Concei\u00e7\u00e3o LD da, Noronha MM, Silva JL da, et al. Sequencing antibody\u2013drug conjugates in metastatic breast cancer: A systematic review, Cancer Treat Rev [Internet]. 2025 Dec 8 [cited 2025 Dec 30];0(0). Available from: https:\/\/www.cancertreatmentreviews.com\/article\/S0305-7372(25)00189-6\/abstract."},{"issue":"7","key":"10.1016\/j.ctrv.2026.103096_b0225","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.annonc.2024.04.002","article-title":"Antibody\u2013drug conjugates in lung and breast cancer: current evidence and future directions\u2014a position statement from the ETOP IBCSG Partners Foundation","volume":"35","author":"Peters","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103096_b0230","doi-asserted-by":"crossref","DOI":"10.1093\/carcin\/bgae082","article-title":"Antibody\u2013drug conjugates in breast cancer","volume":"46","author":"Zhu","year":"2025","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ctrv.2026.103096_b0235","article-title":"Antibody-drug conjugates in breast cancer: toward a molecular perspective into clinical practice","volume":"8","author":"Paz-Manrique","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"18","key":"10.1016\/j.ctrv.2026.103096_b0240","doi-asserted-by":"crossref","first-page":"13726","DOI":"10.3390\/ijms241813726","article-title":"Antibody\u2013drug conjugates in breast cancer: current status and future directions","volume":"24","author":"Mark","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2026.103096_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103830","article-title":"Unveiling the future of breast cancer therapy: cutting-edge antibody-drug conjugate strategies and clinical outcomes","volume":"78","author":"Sun","year":"2024","journal-title":"Breast"},{"key":"10.1016\/j.ctrv.2026.103096_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104090","article-title":"Next-generation antibody-drug conjugates for breast cancer: moving beyond HER2 and TROP2","volume":"190","author":"Schlam","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"issue":"18","key":"10.1016\/j.ctrv.2026.103096_b0255","article-title":"Use of antibody\u2013drug conjugates in the early setting of breast cancer","volume":"1","author":"Koukoutzeli","year":"2024","journal-title":"Clin Med Insights Oncol"},{"key":"10.1016\/j.ctrv.2026.103096_b0260","doi-asserted-by":"crossref","DOI":"10.20892\/j.issn.2095-3941.2024.0486","article-title":"Antibody-drug conjugates in breast cancer: advances and prospects","author":"Shi","year":"2025","journal-title":"Cancer Biol Med [Internet]"},{"key":"10.1016\/j.ctrv.2026.103096_b0265","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jconrel.2023.05.032","article-title":"Bispecific antibodies for targeted delivery of anti-cancer therapeutic agents: a review","volume":"359","author":"Beishenaliev","year":"2023","journal-title":"J Control Release Off J Control Release Soc"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103096_b0270","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1038\/s41467-021-23793-7","article-title":"Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance","volume":"12","author":"Yamazaki","year":"2021","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103096_b0275","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1093\/annonc\/mdz159","article-title":"Does adjuvant therapy reduce postmetastatic survival?","volume":"30","author":"Fink","year":"2019","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103096_b0280","doi-asserted-by":"crossref","first-page":"e867","DOI":"10.1093\/oncolo\/oyad137","article-title":"Real-world impact of adjuvant anti-HER2 treatment on characteristics and outcomes of women with HER2-positive metastatic breast cancer in the ESME program","volume":"28","author":"Le Du","year":"2023","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103096_b0285","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","article-title":"Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis","volume":"26","author":"Spring","year":"2020","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103096_b0290","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.annonc.2020.11.007","article-title":"Circulating tumor DNA in neoadjuvant treated breast cancer reflects response and survival","volume":"32","author":"Magbanua","year":"2020","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"25","key":"10.1016\/j.ctrv.2026.103096_b0295","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1200\/JCO.19.00882","article-title":"Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2\u2013positive breast cancer: three-year outcomes from the phase III KRISTINE study","volume":"37","author":"Hurvitz","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103096_b0300","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10549-024-07333-7","article-title":"Long-term outcomes of neoadjuvant trastuzumab emtansine\u2009+\u2009pertuzumab (T-DM1\u2009+\u2009P) and docetaxel\u2009+\u2009carboplatin\u2009+\u2009trastuzumab\u2009+\u2009pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)","volume":"207","author":"Takano","year":"2024","journal-title":"Breast Cancer Res Treat"},{"issue":"22","key":"10.1016\/j.ctrv.2026.103096_b0305","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1200\/JCO.22.01816","article-title":"De-escalated neoadjuvant trastuzumab-emtansine with or without endocrine therapy versus trastuzumab with endocrine therapy in HR+\/HER2+ early breast cancer: 5-year survival in the WSG-ADAPT-TP trial","volume":"41","author":"Harbeck","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103096_b0310","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS623","article-title":"TRIO-US B-12 TALENT: phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early-stage breast cancer","author":"Hurvitz","year":"2022","journal-title":"J Clin Oncol [Internet]"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103096_b0315","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.annonc.2023.11.018","article-title":"Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial\u2606","volume":"35","author":"Spring","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103096_b0320","doi-asserted-by":"crossref","unstructured":"Abelman RO, McLaughlin S, Fell GG, Garrido-Castro AC, Lynce F, Trippa L, et al. A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG\/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial. J Clin Oncol. 2025 June;43(16_suppl):511\u2013511.","DOI":"10.1200\/JCO.2025.43.16_suppl.511"},{"key":"10.1016\/j.ctrv.2026.103096_b0325","unstructured":"Liu Z. Phase II Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer [Internet]. clinicaltrials.gov; 2024 Oct [cited 2025 Mar 6]. Report No.: NCT05911958. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05911958."},{"key":"10.1016\/j.ctrv.2026.103096_b0330","doi-asserted-by":"crossref","first-page":"S331","DOI":"10.1016\/j.annonc.2024.08.218","article-title":"276P SHR-A1811 in combination with pyrotinib as neoadjuvant treatment for HER2-positive breast cancer (HER2+ BC): Preliminary results from MUKDEN 07","volume":"35","author":"Liu","year":"2024","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103096_b0335","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ccell.2025.03.017","article-title":"Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer","volume":"43","author":"Ma","year":"2025","journal-title":"Cancer Cell"},{"issue":"12_Supplement","key":"10.1016\/j.ctrv.2026.103096_b0340","doi-asserted-by":"crossref","first-page":"LB1","DOI":"10.1158\/1557-3265.SABCS24-LB1-06","article-title":"Abstract LB1-06: Primary results of SOLTI VALENTINE: neoadjuvant randomized phase II trial of HER3-DXd alone or in combination with letrozole for high-risk hormone receptor positive (HR+)\/HER2-negative (neg) early breast cancer (EBC)","volume":"31","author":"Oliveira","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103096_b0345","unstructured":"Harbeck N, Modi S, Pusztai L, Ohno S, Wu J, Kim SB, et al. Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial. Ann Oncol [Internet]. 2025 Oct 21 [cited 2025 Oct 27];0(0). Available from: https:\/\/www.annalsofoncology.org\/article\/S0923-7534(25)04968-3\/fulltext?utm_campaign=ESMO&utm_contentcategory=#Primary-clinical."},{"key":"10.1016\/j.ctrv.2026.103096_b0350","article-title":"26P Revisiting HER2-low in HR+\/HER2\u2212 early breast cancer: clinicopathological features and predictors for pathological response","volume":"10","author":"Pogoda","year":"2025","journal-title":"ESMO Open [Internet]"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103096_b0355","doi-asserted-by":"crossref","first-page":"644","DOI":"10.3390\/medicina61040644","article-title":"HER2-low breast cancer\u2014current knowledge and future directions","volume":"61","author":"Shaaban","year":"2025","journal-title":"Medicina (Mex)"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103096_b0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102989","article-title":"Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer","volume":"9","author":"Curigliano","year":"2024","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103096_b0365","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial","volume":"29","author":"Mosele","year":"2023","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103096_b0370","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S1470-2045(13)70477-7","article-title":"The immune system and response to HER2-targeted treatment in breast cancer","volume":"15","author":"Bianchini","year":"2014","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103096_b0375","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S1470-2045(19)30088-9","article-title":"Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study","volume":"20","author":"Shitara","year":"2019","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.ctrv.2026.103096_b0380","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"issue":"66","key":"10.1016\/j.ctrv.2026.103096_b0385","first-page":"169","article-title":"Antibody-drug conjugates targeting TROP-2: clinical development in metastatic breast cancer","volume":"18","author":"Shastry","year":"2022","journal-title":"Breast Off J Eur Soc Mastology"},{"issue":"23","key":"10.1016\/j.ctrv.2026.103096_b0390","doi-asserted-by":"crossref","first-page":"5936","DOI":"10.3390\/cancers14235936","article-title":"Trop-2 as a therapeutic target in breast cancer","volume":"14","author":"Sakach","year":"2022","journal-title":"Cancers"},{"issue":"15","key":"10.1016\/j.ctrv.2026.103096_b0395","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1200\/JCO.23.01409","article-title":"Final results from the randomized phase III ascent clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression","volume":"42","author":"Bardia","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103096_b0400","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1056\/NEJMe2206661","article-title":"DESTINY-changing results for advanced breast cancer","volume":"387","author":"Hurvitz","year":"2022","journal-title":"N Engl J Med"},{"issue":"9_Supplement","key":"10.1016\/j.ctrv.2026.103096_b0405","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-PO3-20-06","article-title":"Abstract PO3-20-06: TRUDI: a phase II study of neoadjuvant TRastuzumab derUxtecan and Durvalumab for stage III HER2-expressing Inflammatory breast cancer","volume":"84","author":"Tarantino","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103096_b0410","unstructured":"Liu Z. Phase II Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer [Internet]. clinicaltrials.gov; 2024 Oct [cited 2025 Aug 18]. Report No.: NCT05911958. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05911958."},{"key":"10.1016\/j.ctrv.2026.103096_b0415","unstructured":"AstraZeneca. A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001; TROPION-Breast04) [Internet]. clinicaltrials.gov; 2025 Dec [cited 2025 Dec 23]. Report No.: NCT06112379. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06112379."},{"key":"10.1016\/j.ctrv.2026.103096_b0420","unstructured":"Wang H. A Multicenter, Prospective Phase II Single-arm Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment with T-DXd in Combination with an Immune Checkpoint Inhibitor in HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer [Internet]. clinicaltrials.gov; 2024 Dec [cited 2025 Aug 18]. Report No.: NCT06733233. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06733233."},{"key":"10.1016\/j.ctrv.2026.103096_b0425","doi-asserted-by":"crossref","unstructured":"Harbeck N, Braun M, Gluz O, Schmid P, Graeser MK, Hartkopf AD, et al. Neoadjuvant dynamic marker-adjusted personalized therapy comparing trastuzumab-deruxtecan versus pacli-\/docetaxel + carboplatin + trastuzumab + pertuzumab in HER2+ early breast cancer: WSG-ADAPT-HER2-IV. J Clin Oncol. 2024 June;42(16_suppl):TPS631\u2013TPS631.","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS631"},{"key":"10.1016\/j.ctrv.2026.103096_b0430","unstructured":"West German Study Group. NeoAdjuvant Dynamic Marker - Adjusted Personalized Therapy Comparing Sacituzumab Govitecan Versus Sacituzumab Govitecan+Pembrolizumab in Low-risk, Triple-negative Early Breast Cancer (ADAPT-TN-III) [Internet]. clinicaltrials.gov; 2025 Aug [cited 2025 Aug 18]. Report No.: NCT06081244. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06081244."},{"key":"10.1016\/j.ctrv.2026.103096_b0435","unstructured":"QuantumLeap Healthcare Collaborative. I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2) [Internet]. clinicaltrials.gov; 2025 Aug [cited 2025 Aug 18]. Report No.: NCT01042379. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01042379."},{"key":"10.1016\/j.ctrv.2026.103096_b0440","unstructured":"Liu C. Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Stage II-III HER2-positive Breast Cancer Patients Who Have Poor Outcomes After Treatment With Trastuzumab and Pertuzumab [Internet]. clinicaltrials.gov; 2022 Sept [cited 2025 Mar 6]. Report No.: NCT04983121. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04983121."},{"key":"10.1016\/j.ctrv.2026.103096_b0445","unstructured":"Liu C. A Randomized, Open Label, Multi-center Phase II-III Neoadjuvant Study Comparing the Efficacy and Safety of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) in Patients With HER2-positive Breast Cancer [Internet]. clinicaltrials.gov; 2024 Oct [cited 2025 Mar 6]. Report No.: NCT05426486. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05426486."},{"key":"10.1016\/j.ctrv.2026.103096_b0450","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.breast.2022.01.006","article-title":"Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer","volume":"62","author":"Harbeck","year":"2022","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103096_b0455","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12916-018-1017-7","article-title":"Adaptive designs in clinical trials: why use them, and how to run and report them","volume":"16","author":"Pallmann","year":"2018","journal-title":"BMC Med"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103096_b0460","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/CCO.0000000000000583","article-title":"Window of opportunity trials for biomarker discovery in breast cancer","volume":"31","author":"Arnedos","year":"2019","journal-title":"Curr Opin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103096_b0465","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41591-022-01681-x","article-title":"Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery","volume":"28","author":"Marron","year":"2022","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103096_b0470","article-title":"SOLTI-1805 TOT-HER3 study concept: a window-of-opportunity trial of patritumab deruxtecan, a HER3 directed antibody drug conjugate, in patients with early breast cancer","volume":"23","author":"Pascual","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103096_b0475","doi-asserted-by":"crossref","first-page":"5826","DOI":"10.1038\/s41467-024-50056-y","article-title":"Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response","volume":"15","author":"Bras\u00f3-Maristany","year":"2024","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103096_b0480","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.annonc.2023.05.004","article-title":"Patritumab deruxtecan in untreated hormone receptor-positive\/HER2-negativeearly breast cancer: final results from part a of the window-of-opportunity SOLTI TOT-HER3 pre-operative study","volume":"34","author":"Oliveira","year":"2023","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103096_b0485","article-title":"124O Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive\/HER2-negative (HR+\/HER2-) and triple-negative breast cancer (TNBC): results of part B of SOLTI TOT-HER3 window of opportunity trial","volume":"8","author":"Oliveira","year":"2023","journal-title":"ESMO Open [Internet]"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103096_b0490","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx013","article-title":"Adaptive clinical trials: advantages and disadvantages of various adaptive design elements","volume":"109","author":"Korn","year":"2017","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2026.103096_b0495","article-title":"Key design considerations for adaptive clinical trials: a primer for clinicians","volume":"8","author":"Thorlund","year":"2018","journal-title":"BMJ"},{"issue":"25","key":"10.1016\/j.ctrv.2026.103096_b0500","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1002\/sim.5404","article-title":"Bayesian clinical trials in action","volume":"31","author":"Lee","year":"2012","journal-title":"Stat Med"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103096_b0505","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s12609-019-00334-2","article-title":"I-SPY 2: a neoadjuvant adaptive clinical trial designed to improve outcomes in high-risk breast cancer","volume":"11","author":"Wang","year":"2019","journal-title":"Curr Breast Cancer Rep"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103096_b0510","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1038\/s41591-024-03267-1","article-title":"Datopotamab\u2013deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial","volume":"30","author":"Shatsky","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103096_b0515","article-title":"Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: results from the I-SPY2.2 trial","author":"Trivedi","year":"2024","journal-title":"J Clin Oncol [Internet]"},{"key":"10.1016\/j.ctrv.2026.103096_b0520","unstructured":"ResearchGate [Internet]. [cited 2025 May 11]. Abstract PD1-10: Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II\/III breast cancer: Results from the I-SPY 2 TRIAL. Available from: https:\/\/www.researchgate.net\/publication\/349322271_Abstract_PD1-10_Evaluation_of_SGN-LIV1a_followed_by_AC_in_high-risk_HER2_negative_stage_IIIII_breast_cancer_Results_from_the_I-SPY_2_TRIAL."},{"key":"10.1016\/j.ctrv.2026.103096_b0525","unstructured":"QuantumLeap Healthcare Collaborative. I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2) [Internet]. clinicaltrials.gov; 2024 Oct [cited 2025 May 11]. Report No.: NCT01042379. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01042379."},{"key":"10.1016\/j.ctrv.2026.103096_b0530","unstructured":"Pohlmann PR, Rugo HS, et al. Pathologic complete response rates (pCR) after the novel HER2 ADC ARX788: Results from the I-SPY2.2 trial. In San Antonio: Rapid Fire 5; 2025."},{"issue":"6","key":"10.1016\/j.ctrv.2026.103096_b0535","doi-asserted-by":"crossref","DOI":"10.1111\/eci.70001","article-title":"Adverse events and impact on quality of life of antibody\u2010drug conjugates in the treatment of metastatic breast cancer: a systematic review and meta\u2010analysis","volume":"55","author":"Perachino","year":"2025","journal-title":"Eur J Clin Invest"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103096_b0540","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/cai2.97","article-title":"Treatment\u2010related adverse events of antibody\u2010drug conjugates in clinical trials: a systematic review and meta\u2010analysis","volume":"2","author":"Li","year":"2023","journal-title":"Cancer Innov"},{"key":"10.1016\/j.ctrv.2026.103096_b0545","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-25-0682","article-title":"Immune reprogramming of tumor microenvironments by cytotoxic antibody-drug conjugate payloads","author":"Chakravorty","year":"2025","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103096_b0550","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jamaoncol.2025.0207","article-title":"Selective elimination of breast surgery for invasive breast cancer: a nonrandomized clinical trial","volume":"11","author":"Kuerer","year":"2025","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103096_b0555","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s00228-025-03915-6","article-title":"Economic evaluation of antibody-drug conjugates (ADCs) in patients with breast cancer: systematic review","volume":"81","author":"Rezaei","year":"2025","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103096_b0560","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1007\/s11912-024-01582-x","article-title":"Economics of antibody drug conjugates (ADCs): innovation, investment and market dynamics","volume":"26","author":"Bhushan","year":"2024","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ctrv.2026.103096_b0565","unstructured":"Daiichi Sankyo. A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Participants With High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy (DESTINY-Breast05) [Internet]. clinicaltrials.gov; 2025 May [cited 2025 Dec 23]. Report No.: NCT04622319. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04622319."},{"key":"10.1016\/j.ctrv.2026.103096_b0570","unstructured":"Jiangsu HengRui Medicine Co., Ltd. A Phase III, Multicenter, Randomized, Open-Label, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy [Internet]. clinicaltrials.gov; 2025 Apr [cited 2025 Dec 23]. Report No.: NCT06126640. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06126640."},{"key":"10.1016\/j.ctrv.2026.103096_b0575","unstructured":"GBG Forschungs GmbH. Phase III Postneoadjuvant Study Evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in Primary HER2-negative Breast Cancer Patients With High Relapse Risk After Standard Neoadjuvant Treatment - SASCIA [Internet]. clinicaltrials.gov; 2025 Nov [cited 2025 Dec 23]. Report No.: NCT04595565. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04595565."},{"key":"10.1016\/j.ctrv.2026.103096_b0580","unstructured":"German Cancer Research Center. Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer - a Multicenter, Open-label, Umbrella Phase-II Study - COGNITION-GUIDE [Internet]. clinicaltrials.gov; 2025 Mar [cited 2025 Dec 23]. Report No.: NCT05332561. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05332561."},{"key":"10.1016\/j.ctrv.2026.103096_b0585","unstructured":"MedSIR. Chemotherapy-Free pCR-Guided Strategy With Subcutaneous Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer (PHERGAIN-2) [Internet]. clinicaltrials.gov; 2025 Nov [cited 2025 Dec 23]. Report No.: NCT04733Available from: https:\/\/clinicaltrials.gov\/study\/NCT04733118."},{"key":"10.1016\/j.ctrv.2026.103096_b0590","unstructured":"Hoffmann-La Roche. A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy [Internet]. clinicaltrials.gov; 2025 Dec [cited 2025 Dec 23]. Report No.: NCT04873362. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04873362."},{"key":"10.1016\/j.ctrv.2026.103096_b0595","unstructured":"Alliance for Clinical Trials in Oncology. The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib [Internet]. clinicaltrials.gov; 2025 Oct [cited 2025 Dec 23]. Report No.: NCT04457596. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04457596."},{"key":"10.1016\/j.ctrv.2026.103096_b0600","unstructured":"Mittendorf EA. A Single Arm Phase 2 Trial of Atezolizumab With Sacituzumab Govitecan to Prevent Recurrence in Triple Negative Breast Cancer (ASPRIA) [Internet]. clinicaltrials.gov; 2025 Aug [cited 2025 Dec 23]. Report No.: NCT04434040. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04434040."},{"key":"10.1016\/j.ctrv.2026.103096_b0605","unstructured":"Gilead Sciences. A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy [Internet]. clinicaltrials.gov; 2025 Nov [cited 2025 Dec 23]. Report No.: NCT05633654. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05633654."},{"key":"10.1016\/j.ctrv.2026.103096_b0610","unstructured":"AstraZeneca. A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03) [Internet]. clinicaltrials.gov; 2025 Dec [cited 2025 Dec 23]. Report No.: NCT05629585. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05629585."},{"key":"10.1016\/j.ctrv.2026.103096_b0615","unstructured":"AstraZeneca. A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd Followed by THP Compared to ddAC-THP in Participants With High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11) [Internet]. clinicaltrials.gov; 2025 Feb [cited 2025 Mar 6]. Report No.: NCT05113251. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05113251."},{"key":"10.1016\/j.ctrv.2026.103096_b0620","unstructured":"West German Study Group. NeoAdjuvant Dynamic Marker - Adjusted Personalized Therapy Comparing Trastuzumab-deruxtecan Versus Pacli-/Docetaxel+Carboplatin+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer [Internet]. clinicaltrials.gov; 2025 Nov [cited 2025 Dec 23]. Report No.: NCT05704829. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05704829."},{"issue":"24","key":"10.1016\/j.ctrv.2026.103096_b0625","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12885-024-11851-4","article-title":"Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study)","volume":"17","author":"Dowling","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2026.103096_b0630","doi-asserted-by":"crossref","first-page":"S356","DOI":"10.1016\/j.annonc.2024.08.278","article-title":"339TiP a randomized trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer (ARIADNE)","volume":"35","author":"Foukakis","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103096_b0635","unstructured":"Shao Z. Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Versus Standard Treatment for Medium-risk HER2-positive Early Breast Cancer: a Randomized, Multi-center Trial (EXTEND) [Internet]. clinicaltrials.gov; 2024 Aug [cited 2025 Dec 23]. Report No.: NCT06548178. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06548178."},{"key":"10.1016\/j.ctrv.2026.103096_b0640","unstructured":"QuantumLeap Healthcare Collaborative. I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2) [Internet]. clinicaltrials.gov; 2024 Oct [cited 2025 Mar 6]. Report No.: NCT01042379. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01042379."},{"key":"10.1016\/j.ctrv.2026.103096_b0645","unstructured":"Xijing Hospital. Phase II Clinical Study to Evaluate the Efficacy and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Coupling Agent (RC48-ADC) for Neoadjuvant Treatment of Breast Cancer With Positive HER2 Expression (Seraph) [Internet]. clinicaltrials.gov; 2021 Nov [cited 2025 Mar 6]. Report No.: NCT05134519. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05134519."},{"key":"10.1016\/j.ctrv.2026.103096_b0650","unstructured":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd. A Phase 2, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of TQB2102 for Injection for Neoadjuvant Treatment of Breast Cancer With Positive HER2 Expression [Internet]. clinicaltrials.gov; 2024 May [cited 2025 Mar 6]. Report No.: NCT06198751. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06198751."},{"key":"10.1016\/j.ctrv.2026.103096_b0655","unstructured":"Jonsson Comprehensive Cancer Center. A Phase II, Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of Trastuzumab Deruxtecan (DS-8201a) With or Without Anastrozole for HER2 Low Hormone Receptor Positive (HR+) Breast Cancer in the Neoadjuvant Setting [Internet]. clinicaltrials.gov; 2025 Nov [cited 2025 Dec 23]. Report No.: NCT04553770. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04553770."},{"key":"10.1016\/j.ctrv.2026.103096_b0660","unstructured":"Lynce F. TRUDI: A Phase II Study of Neoadjuvant Trastuzumab Deruxtecan and Durvalumab for Stage III, HER2-expressing Inflammatory Breast Cancer [Internet]. clinicaltrials.gov; 2025 Sept [cited 2025 Dec 23]. Report No.: NCT05795101. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05795101."},{"key":"10.1016\/j.ctrv.2026.103096_b0665","unstructured":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. A Multicenter, Single-arm, Phase 2 Study of Neoadjuvant SHR-A1811 Plus Adebrelimab Injection for Early-stage or Locally Advanced HR Negative or Low Expression/HER2 Low Expression Breast Cancer [Internet]. clinicaltrials.gov; 2024 Sept [cited 2025 Dec 23]. Report No.: NCT06592625. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06592625."},{"key":"10.1016\/j.ctrv.2026.103096_b0670","unstructured":"Liu C. A Phase II Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients [Internet]. clinicaltrials.gov; 2024 July [cited 2025 Mar 6]. Report No.: NCT05635487. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05635487."},{"key":"10.1016\/j.ctrv.2026.103096_b0675","unstructured":"Liu S. A Single-arm, Single-center Exploratory Clinical Study of Disitamab Vedotin Combined With Penpulimab as Neoadjuvant Therapy in the Treatment of HER2-low Early or Locally Advanced Breast Cancer [Internet]. clinicaltrials.gov; 2023 Feb [cited 2025 Mar 6]. Report No.: NCT05726175. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05726175."},{"key":"10.1016\/j.ctrv.2026.103096_b0680","unstructured":"Spring LM. A Phase 2 Study of Response-guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Patients With Localized Triple-Negative Breast Cancer (NeoSTAR) [Internet]. clinicaltrials.gov; 2024 Mar [cited 2025 Mar 6]. Report No.: NCT04230109. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04230109."},{"key":"10.1016\/j.ctrv.2026.103096_b0685","unstructured":"M.D. Anderson Cancer Center. A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC) [Internet]. clinicaltrials.gov; 2024 Dec [cited 2025 Mar 6]. Report No.: NCT05675579. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05675579."},{"key":"10.1016\/j.ctrv.2026.103096_b0690","unstructured":"Liu Z. A Phase II Study of SHR-A2102 in Combination With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer [Internet]. clinicaltrials.gov; 2025 June [cited 2025 Dec 23]. Report No.: NCT06819319. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06819319."},{"key":"10.1016\/j.ctrv.2026.103096_b0695","unstructured":"Dillon P. Pilot Study of the Antibody-drug Conjugate Glembatumumab Vedotin (CDX-011) Following Doxorubicin (Adriamycin) and Cytoxan as Neo-adjuvant Therapy in Glycoprotein NMB-expressing High Risk Triple Negative Breast Cancer [Internet]. clinicaltrials.gov; 2024 Dec [cited 2025 Dec 23]. Report No.: NCT03473691. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03473691."},{"key":"10.1016\/j.ctrv.2026.103096_b0700","unstructured":"SOLTI Breast Cancer Research Group. A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression [Internet]. clinicaltrials.gov; 2023 June [cited 2025 Mar 6]. Report No.: NCT04610528. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04610528."},{"key":"10.1016\/j.ctrv.2026.103096_b0705","unstructured":"SOLTI Breast Cancer Research Group. A Phase 2 Trial of neoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan (HER3-DXd; U3-1402) With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial [Internet]. clinicaltrials.gov; 2023 Sept [cited 2025 Mar 6]. Report No.: NCT05569811. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05569811."}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T07:35:33Z","timestamp":1773041733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226000101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":141,"alternative-id":["S0305737226000101"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103096","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrating antibody-drug conjugates into the management of early breast cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103096","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103096"}}